XmAb®22841 for Melanoma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York, NY
Melanoma+37 More
XmAb®22841 - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This study is evaluating whether a drug may help treat cancer.

See full description

Eligible Conditions

  • Melanoma
  • Colorectal Carcinoma (CRC)
  • Small Cell Lung Carcinoma
  • Endometrial Carcinoma
  • Penile Squamous Cell Carcinoma (PSCC)
  • Nasopharyngeal Carcinoma
  • Cervical Carcinoma
  • Breast Cancer (Triple Negative Breast Cancer (TNBC))
  • Squamous Cell Carcinoma of the Head and Neck
  • Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
  • Prostate Cancer
  • Ovarian Cancer (Epithelial)
  • Fallopian Tubes Cancer
  • Primary Peritoneal Carcinoma
  • Intrahepatic Cholangiocarcinoma
  • Squamous Cell Anal Cancer
  • Renal Cell Adenocarcinoma
  • Advanced or Metastatic Solid Tumors
  • Vulvar Squamous Cell Carcinoma
  • Carcinoma, Pancreatic
  • Hepatocellular Carcinoma
  • Transitional Cell, Carcinoma
  • Non-small Cell Lung Carcinoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Melanoma

Study Objectives

This trial is evaluating whether XmAb®22841 will improve 1 primary outcome in patients with Melanoma. Measurement will happen over the course of 56 Days.

56 Days
Safety and tolerability profile of XmAb22841 assessed by rates of treatment-related adverse events (AEs), graded by CTCAE v4.03.

Trial Safety

Safety Progress

1 of 3

Other trials for Melanoma

Trial Design

2 Treatment Groups

Arm 1
1 of 2
Arm 2
1 of 2
Experimental Treatment

This trial requires 242 total participants across 2 different treatment groups

This trial involves 2 different treatments. XmAb®22841 is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.

Arm 1
Biological
Arm 1: XmAb®22841 Monotherapy
Arm 2Arm 2: Combination of XmAb®22841 and Pembrolizumab (Keytruda®)

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 56 days
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 56 days for reporting.

Closest Location

Laura & Isaac Perlmutter Cancer Center at NYU Langone Health - New York, NY

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
PART A (Dose Escalation Cohorts)
All subjects' cancer must have progressed after treatment with all available therapies that are known to confer clinical benefit, or are intolerant to treatment, or refuse standard treatment.
All subjects must have adequate archival tumor, or give consent to a fresh tumor biopsy.
Subjects have an ECOG performance status of 0-1.
Melanoma
Cervical carcinoma
Pancreatic carcinoma
Breast carcinoma that is estrogen receptor, progesterone receptor, and Her2 negative (TNBC)
Hepatocellular carcinoma
Urothelial carcinoma

Patient Q&A Section

What is carcinoma, non-small-cell lung?

"This was the most common cancer in the United States. The peak incidence for adults ages 20-34 years with this type of lung cancer is expected to be in the future." - Anonymous Online Contributor

Unverified Answer

Has xmab®22841 proven to be more effective than a placebo?

"Findings from a recent study provide the first compelling evidence that XMab is not more effective than a placebo for the management of advanced and refractory solid tumours." - Anonymous Online Contributor

Unverified Answer

What are the signs of carcinoma, non-small-cell lung?

"The signs of carcinoma, non-small-cell lung vary according to the organ of origin and metastasis. A positive sign is a symptom or sign that should be evaluated with a careful medical history and physical examination." - Anonymous Online Contributor

Unverified Answer

What are common treatments for carcinoma, non-small-cell lung?

"A number of systemic or inhaled therapies have been found to be effective. In addition, certain therapies, such as chemotherapy, may be used to decrease pain in patients with lung cancer. The most effective form of treatment may be determined by a multimodal approach, with different therapies being employed concurrently." - Anonymous Online Contributor

Unverified Answer

What causes carcinoma, non-small-cell lung?

"Chronic or chronic smoking may cause lung carcinoma, and is more likely than the age-adjusted rate in men born before the turn of the 20th century. Smoking decreases lung carcinoma risk in women, presumably by a shared defect in the proliferative potential of the normal epithelium. Larger studies may help in determining the role and mechanisms of genetic susceptibility in lung carcinoma." - Anonymous Online Contributor

Unverified Answer

How many people get carcinoma, non-small-cell lung a year in the United States?

"The overall and racial/ethnic differences in lung cancer incidence suggest that current screening practices in the United States are suboptimal at detecting lung malignancies in the general population and that future screening recommendations should target high-risk subgroups such as people who are current smokers and/or African-Americans." - Anonymous Online Contributor

Unverified Answer

Can carcinoma, non-small-cell lung be cured?

"No patients who received a curative surgical resection were known to have been alive at 30 months after surgery. When local recurrence or distant metastasis occurred in the curative group, the median survival time was 17 months postoperatively, while in the operative secondarily group, the median survival time was 36 months postoperatively." - Anonymous Online Contributor

Unverified Answer

What are the common side effects of xmab®22841?

"Itching, dry skin, increased lacrimation, headache, fever and weight gain are very common side effects of Xmab™ 22841. They may occur during treatment or for weeks or months after treatment. All these side effects are mild and easily manageable, thus Xmab™ 22841 causes no more side effects than placebo, when used for indications as listed in the clinical trials. Symptoms and signs can be mild or moderate in many indications such as advanced squamous cell carcinoma of the prostate, renal renal cell carcinoma and metastatic melanoma or sarcoma of unknown primary origin." - Anonymous Online Contributor

Unverified Answer

What is the primary cause of carcinoma, non-small-cell lung?

"Primary pulmonary malignancy could be caused by external factors, as we found that the group of patients with a history of previous pulmonary malignancy was on average younger than the group without such a history; the same applies to the group of smokers. Recent findings suggest the absence of an important role for environmental factors in the development of lung malignancies. A prospective study is needed to assess the association between environmental smoking history and lung cancer development." - Anonymous Online Contributor

Unverified Answer

What is the average age someone gets carcinoma, non-small-cell lung?

"Lung carcinomas are rare in younger patients. Larger-scale studies are required to determine the age at onset to allow more optimal staging and early detection." - Anonymous Online Contributor

Unverified Answer

What does xmab®22841 usually treat?

"We show that Xmab22841 is effective in eradicating XMRV in human prostate cancer tissue and tumor-derived cell cultures. XMRV may be an etiologic agent in prostate cancer or it may not. We therefore propose to test to the presence of an XMRV infection in patients with prostate cancer using Xmab22841 so that XMRV can be identified as either a benign or a pathogenic agent." - Anonymous Online Contributor

Unverified Answer

What are the latest developments in xmab®22841 for therapeutic use?

"In the last quarter of the twentieth century, the use of XMab is increasing in the USA. The treatment of metastatic and locally advanced NSCLC with XMab is safe." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Melanoma by sharing your contact details with the study coordinator.